1. Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies
- Author
-
Christina Alidousty, Sabine Merkelbach-Bruse, Till Baar, Susann Zupp, Reinhard Buettner, Hans Christian Reinhardt, Anne M. Schultheis, Jürgen Wolf, Anna Kron, Barbara Holz, Elke Binot, Svenja Wagener, Carina Heydt, and Roberta Castiglione
- Subjects
0301 basic medicine ,Oncology ,Neuroblastoma RAS viral oncogene homolog ,Male ,Mutation rate ,Pathology ,Lung Neoplasms ,medicine.disease_cause ,GTP Phosphohydrolases ,0302 clinical medicine ,Mutation Rate ,Carcinoma, Non-Small-Cell Lung ,Genetics research ,Molecular Targeted Therapy ,medicine.diagnostic_test ,Proto-Oncogene Proteins c-mdm2 ,Middle Aged ,Proto-Oncogene Proteins c-met ,Prognosis ,MET Exon 14 Skipping Mutation ,Phenotype ,030220 oncology & carcinogenesis ,Female ,KRAS ,medicine.medical_specialty ,Antineoplastic Agents ,Article ,Genomic Instability ,Pathology and Forensic Medicine ,Proto-Oncogene Proteins p21(ras) ,03 medical and health sciences ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,Genetic Predisposition to Disease ,Lung cancer ,Allele frequency ,Protein Kinase Inhibitors ,Aged ,Retrospective Studies ,business.industry ,HMGA2 Protein ,Gene Amplification ,Cyclin-Dependent Kinase 4 ,Membrane Proteins ,Retrospective cohort study ,Translational research ,medicine.disease ,030104 developmental biology ,Mutation ,Tumor Suppressor Protein p53 ,business ,Non-small-cell lung cancer ,Fluorescence in situ hybridization - Abstract
Although non-small-cell lung cancer is a leading cause of cancer-related deaths, the molecular characterization and classification of its genetic alterations has drastically changed treatment options and overall survival within the last few decades. In particular, tyrosine kinase inhibitors targeting specific molecular alterations, among other MET, have greatly improved the prognosis of non-small-cell lung cancer patients. Here, we compare the genomic background of a subset of non-small-cell lung cancer cases harboring either a MET high-level amplification (n = 24) or a MET exon 14 skipping mutation (n = 26), using next-generatison sequencing, fluorescence in situ hybridization, immunohistochemistry, and Nanostring nCounter® technology. We demonstrate that the MET-amplified cohort shows a higher genetic instability, compared with the mutant cohort (p
- Published
- 2018